SecondWave Systems Raises $7 Million to Enhance Clinical Development
SecondWave Systems, Inc., a pioneering clinical-stage medical device company, has successfully secured $7 million in a Series A financing round aimed at expediting the clinical development of its groundbreaking ultrasound-based therapy for inflammatory disorders. The funding round was led by Treo Ventures, joined by a significant healthcare strategic partner, as well as Scientific Health Development, Discovery Capital of the University of Minnesota, and SSBCI funds. This substantial capital infusion will enable SecondWave to proceed with its next clinical study, building on the encouraging outcomes of its first-in-human study, which showcased a notable reduction in rheumatoid arthritis disease activity.
Building on Prior Achievements and Funding
This new financing round reflects the ongoing commitment of investors to SecondWave's innovative approach, building on previous support from U.S. government agencies, including the Defense Advanced Research Projects Agency (DARPA) and the Advanced Research Projects Agency for Health (ARPA-H). Those prior investments have been instrumental in the research and development of SecondWave MINI™, an innovative, noninvasive, wearable therapeutic ultrasound device designed specifically for treating inflammatory conditions.
Leadership and Vision for Improved Patient Care
Expressing excitement about the new funding, SecondWave's CEO, Anuj Bhardwaj, stated, "As we strive to develop and commercialize the SecondWave MINI as a new class of noninvasive therapy, we are thrilled to embark on this next phase with the strong support of new investors. Our dedicated team at SecondWave is passionately committed to enhancing the quality of life for millions of Americans battling chronic inflammatory disorders." His sentiments were echoed by Mudit K. Jain, PhD, General Partner at Treo Ventures, who emphasized the potential of this novel therapy to significantly improve patient outcomes while also reducing healthcare costs.
Expert Endorsements and Future Potential
SecondWave’s vision is further bolstered by its advisory board member, Paul Peter Tak, MD, PhD, a prominent figure in biotechnology and a physician-scientist renowned for his significant contributions to bioelectronic medicine in autoimmune diseases. He remarked, "As an early innovator demonstrating how implanted vagus nerve stimulation can effectively treat rheumatoid arthritis, I am truly excited about the prospect of widespread adoption of SecondWave's novel approach using noninvasive ultrasound therapy for immune-mediated inflammatory conditions." This endorsement highlights the promising potential of SecondWave’s technology in transforming the landscape of treatment for inflammatory disorders.
Innovation at the Core of SecondWave
SecondWave Systems operates at the forefront of medical technology by developing a unique, noninvasive, and personalized ultrasound stimulation platform aimed at providing both patients and healthcare professionals with an innovative treatment option for serious inflammatory diseases. The SecondWave MINI™ device leverages proprietary low-intensity focused ultrasound technology designed to stimulate the spleen, which may offer novel therapeutic avenues for managing acute and chronic inflammatory disorders, including rheumatoid arthritis.
As the company prepares for further clinical studies, there is heightened anticipation about how this technology may revolutionize the treatment options available to patients grappling with debilitating and life-threatening inflammatory diseases.
Frequently Asked Questions
What is the purpose of the Series A funding for SecondWave Systems?
The funding is intended to accelerate the clinical development of SecondWave's innovative ultrasound-based therapy for inflammatory disorders.
Who led the Series A financing round for SecondWave?
The financing round was led by Treo Ventures alongside a major healthcare strategic partner and other investors.
What is the SecondWave MINI™ device?
It is a first-of-its-kind, noninvasive, wearable therapeutic ultrasound device designed for treating inflammatory diseases.
How does SecondWave's technology work?
It uses proprietary low-intensity focused ultrasound technology to stimulate the spleen and potentially treat various inflammatory conditions.
Who are the key people in SecondWave Systems?
Key individuals include CEO Anuj Bhardwaj and advisory board member Paul Peter Tak, MD, PhD, who is a prominent figure in the biotech field.
